Meeting
Abstract Number: 242
SHM Converge 2021
Background: Opioid overdose in the United States continues to rise. Naloxone is an opioid antagonist that is FDA-approved for reversing opioid overdose. Current CDC guidelines recommend prescribing naloxone to patients at high risk of opioid overdose, including patients with concurrent benzodiazepine use, a prior history of overdose, and those receiving high doses of opioids (>50 […]
Abstract Number: 293
SHM Converge 2021
Background: Opioid use disorder (OUD) is a chronic relapsing disease that has become an epidemic in the United States. Overdoses of prescription and illicit opioids have killed almost 450,000 Americans between 1999-2018 (1). Guidelines on OUD management recommend, in combination with behavioral therapy, opioid agonist therapy as the first-line treatment option with antagonist therapy as an alternative option. OUD-related inpatient admissions represent […]